University of Washington Health Sciences Research Studies Seeking Volunteers

12 item(s) returned.
To access detailed information about a study, click on the study #.

Specific Diseases or Conditions
Study #	Title
2224.00	A Phase 1 / 2, Multi-Center, Open-Label, Dose-Escalation Study of Elotuzummab (Humanized anti-CS1 Monoclonal IgG1 antibody) and Bortezomib in Subjects with Multiple Myeloma Following One to Three Prior Therapies
2161.00	A Phase II Study of Lenalidomide Following Allogeneic Stem Cell Transplant for Multiple Myeloma Patients Who Relapse or Have Disease Progression
1368.00	A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma
2199.00	A Phase IIa, Open-Label, Dose Confirmation Study of Oral Clofarabine in Previously Treated Adult Patients with Myelodysplastic Syndrome (MDS)
1860.00	A Phase III Randomized, Multicenter Study Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors
2245.00	A Phase III, Randomized, Open-Label, 3-Arm Study To Determine The Efficacy And Safety Of Lenalidomide (Revlimid®) Plus Low-Dose Dexamethasone When Given Until Progressive Disease Or For 18 Four-Week Cycles Versus The Combination Of Melphalan, Prednisone, And Thalidomide Given For 12 Six-Week Cycles In Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years Of Age Or Older Or Not Candidates For Stem Cell Transplantation
1938.00	A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial
2345.00	An Open-label, Multicenter, Randomized Phase II Study to Investigate the Safety, Tolerability, and Efficacy of RO5072759 Versus Rituximab in Patients with Relapsed CD20+ Indolent B-cell Non-Hodgkin’s Lymphoma
6817	Combination Pegylated Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma (PLD-BCD)
6562	Dose Escalation Study of Clofarabine in Combination with Cytarabine (ara-C) and G-CSF Priming for Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients
2243.00	Phase 1b Multicenter Dose Escalation Study of Carfilzomib with Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma
2239.00	Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen